Treatment failure patterns are similar between p16− and p16+ oropharyngeal squamous cell carcinomas

Laryngoscope Investigative Otolaryngology

article

Chelsea S. Hamill MD¹  Richard Grant Muller MD¹  Kate Clancy MD¹  Brandon Vu BS²  Shanying Gui PhD²  Jason Eric Thuener MD¹  Jay Wasman MD²  Shawn Li MD¹  Nicole Fowler MD¹  Rod Rezaee MD¹  Pierre Lavertu MD¹  Theodoros N. Teknos MD¹  Quintin Pan PhD¹  Wendi Quinn O'Neill MS, DDS¹ 

[1] Department of Otolaryngology-Head and Neck Surgery, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine;University Hospitals Seidman Cancer Center;Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine;Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine

关键词: disease progression;    head and neck cancer;    oropharyngeal cancer;    p16;    treatment failure;   

DOI  :  10.1002/lio2.779

学科分类：环境科学（综合）

来源: Wiley

【 摘 要 】

Background The incidence of p16+ oropharyngeal squamous cell carcinoma (OPSCC) has been increasing. The notion that p16+ OPSCC has a propensity for atypical and disseminating metastasis has gained traction. We compared treatment failure patterns in p16+ and p16− OPSCC and evaluated survival impact. Methods Retrospective analysis of patients with recurrent/metastatic OPSCC disease between 1/2009 and 12/2019. Results Thirty-eight p16+ and 36 p16− patients were identified. Three distinct failure patterns (distant vs. locoregional, atypical vs. typical, and disseminating vs. non-disseminating) were studied. No significant differences were found between p16+ and p16− patients. Multivariate analysis showed p16 status was an independent prognostic biomarker; p16+ patients have a favorable overall survival compared to p16− patients (HR 0.34, 95% CI 0.16–0.77; P  = .005). Conclusions We challenge the view that p16+ OPSCC exhibits a distinctive treatment failure pattern and showed that p16 status impacts patient survival independent of disease progression.

【 授权许可】

CC BY|CC BY-NC-ND